News
APLMW
0.0160
-15.79%
-0.0030
Weekly Report: what happened at APLM last week (0720-0724)?
Weekly Report · 5h ago
Apollomics files Form 3 as director Yen Hung Hsien reports beneficial ownership
PUBT · 2d ago
Apollomics appoints Hung-Hsien Yen to board after two directors resign
PUBT · 5d ago
Weekly Report: what happened at APLM last week (0713-0717)?
Weekly Report · 07/20 09:10
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/17 17:05
Apollomics Inc trading resumes
TipRanks · 07/17 13:55
Apollomics Inc trading halted, volatility trading pause
TipRanks · 07/17 13:50
Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch
NASDAQ · 07/17 02:52
Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data
NASDAQ · 07/16 03:41
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/15 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/13 17:05
Apollomics regains Nasdaq compliance with $35 million market value requirement
PUBT · 07/13 12:06
Apollomics Regains Nasdaq Compliance
Benzinga · 07/13 12:01
APOLLOMICS REGAINS FULL COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS
Reuters · 07/13 12:00
Weekly Report: what happened at APLM last week (0706-0710)?
Weekly Report · 07/13 09:10
Weekly Report: what happened at APLM last week (0629-0703)?
Weekly Report · 07/06 09:11
Weekly Report: what happened at APLM last week (0622-0626)?
Weekly Report · 06/29 09:10
Apollomics Inc trading resumes
TipRanks · 06/25 16:00
Apollomics Inc trading halted, volatility trading pause
TipRanks · 06/25 15:55
Apollomics Terminates License Agreement With Launxp International
Dow Jones · 06/24 21:59
More
Webull provides a variety of real-time APLMW stock news. You can receive the latest news about APOLLOMICS INC through multiple platforms. This information may help you make smarter investment decisions.
About APLMW
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.